PROVIDER NOTIFICATION OF POLICY CRITERIA CHANGE					
POLICY TITLE	**POLICY NUMBER**	**CRITERIA CHANGE**	**MATERIAL AMENDEMENT**	**EFFECTIVE DATE**	**LINK TO FULL POLICY**
Genetic Test: Biomarker Testing (including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer	2022044	Restricted coverage added for NTRK gene fusion analysis, TMB, RET gene fusion expression, FOLR1 protein expression, BRAF V600E, and liquid ctDNA based testing. 81191-81194, 81301, 81479, 88360, and 81210 added with restricted coverage. NTRK1, NTRK2, and NTRK3 gene fusion analysis of tumor tissue meets Primary Coverage Criteria for individuals with recurrent ovarian cancer to select candidacy for entrectinib, larotrectinib, or repotrectinib. Tumor mutational burden meets Primary Coverage Criteria for individuals with recurrent/persistent ovarian cancer to determine candidacy for pembrolizumab. RET gene fusion expression meets Primary Coverage Criteria for individuals with recurrent/persistent ovarian cancer to determine candidacy for selpercatinib. Folate receptor alpha 1 (FOLR1) protein expression meets Primary Coverage Criteria to determine candidacy for mirvetuximab soravtansine-gynx in individuals with Fra-expressing tumors (greater than or equal to 75% positive tumor cells). BRAF V600E testing meets Primary Coverage Criteria for individuals with recurrent/persistent ovarian cancer to determine candidacy for dabrafenib plus trametinib. Liquid (ctDNA) based testing (Foundation One Liquid CDx [0239U]), to identify individuals who may benefit from the use of olaparib Primary Coverage Criteria when **ALL** of the following criteria are met:	No	03/01/2026	https://secure.arkansasbluecross.com/members/report.aspx?policyNumber=2022044

		• The individual is a candidate for use per drug label of an applicable FDA approved targeted agent • The individual has not had prior testing for the targeted gene(s) of interest in the metastatic setting • There is insufficient tumor tissue available for NGS-based somatic profiling or tissue biopsy is unsafe or considered infeasible due to the individual's clinical condition			